Janux Therapeutics Partners With Bristol-Myers (BMY) on Solid Tumor Therapy
Janux Therapeutics said on January 22 that it has partnered with Bristol-Myers Squibb Company (NYSE:BMY) to develop a new cancer treatment, according to Reuters.
Bristol Myers Squibb Co (BMY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Hourglass Capital Kenneth A. Moffet | 4,330 | $233,560 | 0.05% | |
| 2. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $47.58 | 4,250 | $202,215.00 | 83,513 | 2025-04-25 | Filing | |
| $55.05 | 2,000 | $110,096.00 | 104,626 | 2025-02-20 | Filing | |
| $54.84 | 1,823 | $99,999.97 | 63,932 | 2025-02-14 | Filing | |
| $54.68 | 1,830 | $100,055.25 | 62,109 | 2024-11-01 | Filing | |
| $49.78 | 2,000 | $99,560.00 | 82,672 | 2023-12-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $47.33 | 56,000 | $2,650,480.00 | 167,379 | 2025-09-02 | Filing | |
| $44.23 | 378 | $16,718.94 | 5,066 | 2025-08-02 | Filing | |
| $38.01 | 97 | $3,701.83 | 0 | 2025-05-09 | Filing | |
| $55.62 | 700 | $38,930.50 | 11,760 | 2024-11-04 | Filing | |
| $61.25 | 17,986 | $1,101,642.50 | 27,868 | 2023-08-24 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,704,807 | $361,657,293 | 0.52% | |
| 2. | 5,205,120 | $280,764,173 | 0.16% | |
| 3. | 3,396,965 | $183,232,292 | 0.28% | |
| 4. | 2,726,260 | $147,054,464 | 0.78% | |
| 5. | 2,115,360 | $114,102,518 | 0.32% |
News See All
11 Best Inexpensive Stocks to Buy Now
On January 16, Saira Malik, Nuveen CIO, joined CNBC's 'Closing Bell' to discuss her belief that earnings would propel the market forward, but valuations could bring volatility.
Bristol-Myers (BMY): UBS Turns Bullish as Biotech and Pharma Show Signs of a Recovery
On January 7, UBS upgraded Bristol-Myers Squibb Company (NYSE:BMY) to a Buy from Neutral. The firm lifted its price target sharply to $65, from $46.
Leerink Bullish on Bristol-Myers Squibb Company (BMY) Amid Ample Pipeline Optionality in 2026
On January 13, 2026, Leerink raised its price target on Bristol-Myers Squibb Company (NYSE:BMY) from $54.00 to $60.00, while reiterating an ‘Outperform’ rating.
15 Best High Yield Stocks To Buy
Dividend-paying stocks tend to rise and fall in popularity depending on the mood of the broader market.
Bristol-Myers Squibb (BMY) Upgraded to Buy by UBS, Noting a Skewed Risk/Reward Ratio for the Stock
Bristol-Myers Squibb Company (NYSE:BMY) ranks among the most active blue chip stocks to buy now.
Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026
TheFly reported on January 9 that Scotiabank analyst Louise Chen raised BMY’s price target to $60 from $53 while maintaining a Sector Perform rating.
10 Undervalued Wide Moat Stocks to Buy Right Now
As U.S. markets go further into 2026, they are witnessing a shift in the macro backdrop that is reshaping expectations across asset classes. Following a sluggish 2025, U.S.
Top 10 Oncology Stocks to Buy Now
The oncology market in the United States was estimated at $81.34 billion in 2025 and is expected to reach $211.78 billion by 2034 with a compound annual growth rate of 11.75%.
Hedge Fund Resource Center Billionaire Hedge Funds
